<DOC>
	<DOC>NCT01226407</DOC>
	<brief_summary>Open label, single dose and phase I study. The primary objective: To determine the maximum tolerated dose in Single dose The secondary objective: to evaluate the toxicity in administration to determine desirable dosing amount for phase II to evaluate tumor response in progressive solid cancer patients to evaluate pharmacokinetic/ pharmacodynamic profile.</brief_summary>
	<brief_title>Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile</brief_title>
	<detailed_description>1. Number of Subjects: 28~36, dose escalation (2~6 subject of each step) 2. Adverse Events will be coded to preferred therm and body system using the CTCAE</detailed_description>
	<criteria>from 20 years old to 69 years old diagnosed with progressive solid cancer In spite of standard chemotherapies, the efficacy of the treatment or life extension cannot be expected. Evaluated 01 of ECOG Expected life duration is within 3 months Major surgery except tumorremoval surgery received within 2 weeks of screening. history of CNS metasis hypersensitivy of study drug pregancy or lactating administered other HDAC inhibitor within 4 weeks of screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Solid Tumour</keyword>
</DOC>